Location: United States
The FDA-approved video game targets specific neural systems responsible for attention control to improve ADHD symptoms.
An estimated 9.4% of people aged 2-17 in the USA have attention-deficit/hyperactivity disorder (ADHD). The neurodevelopmental disorder affects the child’s concentration and self-control which can lead to difficulties at school, social issues, low self-esteem, and more. Typically, treatment for ADHD involves medication, therapy, or a combination of the two. A new aid, Akili Interactive’s innovative form of treatment, was cleared by the Food and Drug Administration (FDA) in June 2020. Their product, EndeavorRX, provides treatment in the form of a video game. By aligning therapy into the child’s normal activities, it may increase adherence. The game works by incorporating sensory stimuli and simultaneous motor challenges that have been designed to increase attention control by targeting specific neural systems. The game is for children aged 8-12 years old and requires a prescription. EndeavorRX’s FDA approval was based on the results from 5 clinical studies that showed a significant improvement in ADHD symptoms – It is the first video game ever to be approved as a treatment. The platform can be used as part of a range of therapeutic options for the condition alongside medication.